Clinical Trial Detail

NCT ID NCT02831179
Title Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements no
Sponsors Vanderbilt-Ingram Cancer Center
Indications

VIPoma

thyroid medullary carcinoma

islet cell tumor

adrenal medulla cancer

insulinoma

adrenal carcinoma

somatostatinoma

Merkel cell carcinoma

small intestine carcinoid neuroendocrine tumor

L-cell glucagon-like peptide producing tumor

neuroendocrine tumor

gastrinoma

Therapies

Capecitabine + Temozolomide + Veliparib

Age Groups: adult senior

No variant requirements are available.